首页 | 本学科首页   官方微博 | 高级检索  
     

抗VEGF药物在PDR患者玻璃体切割手术前应用的临床研究
引用本文:丁博宇,顾永昊,董凯,王林,柯根杰. 抗VEGF药物在PDR患者玻璃体切割手术前应用的临床研究[J]. 实用防盲技术, 2021, 0(1): 7-11
作者姓名:丁博宇  顾永昊  董凯  王林  柯根杰
作者单位:安徽医科大学附属省立医院眼科;中国科学技术大学附属第一医院
摘    要:
目的 探讨在增殖性糖尿病性视网膜病变患者进行玻璃体手术之前进行抗VEGF药物治疗对其手术难度、术中术后并发症及疗效情况等的影响.方法 选取安徽省立医院2018-08至2020-05诊断为增殖性糖尿病性视网膜病变(PDR)并拟予以23G玻璃体切割术进行治疗的患者43人50例患眼.将50例患眼分为眼内注药组与对照组,其中眼...

关 键 词:增殖性性糖尿病性视网膜病变  23G玻璃体切割手术  抗血管内皮生长因子

Clinical observation of intravitreal anti-VEGF drugs injection before vitrectomy in patients with PDR
DING Bo-yu,GU Yonghao,DONG Kai,KE Gen-jie. Clinical observation of intravitreal anti-VEGF drugs injection before vitrectomy in patients with PDR[J]. Journal of Practical Preventing Blind, 2021, 0(1): 7-11
Authors:DING Bo-yu  GU Yonghao  DONG Kai  KE Gen-jie
Affiliation:(Department of ophthalmology,the affiliated provincial hospital of Anhui medical university,Hefei 230001 China)
Abstract:
Objetive To investigate the clinical effect of therapy that combines vitrectomy with intravitreal anti-VEGF drug injection in patients with proliferative diabetic retinopathy.Methods Fifty eyes of 43 patients with proliferative diabetic retinopathy(PDR)diagnosed from August 2018 to May 2020 in Anhui Provincial Hospital were selected and treated with 23 G vitrectomy.50 eyes were divided into two groups,17 patients(20 eyes)in the injection group and 30 patients(26 eyes)in the control group.AntiVEGF drugs were injected into the vitreous 3 to 7 days before 23 G vitrectomy in the injection group,while 23 G vitrectomy was performed directly after admission in the control group.The operation time,intraoperative and postoperative complications and the visual acuity of the two groups were observed and analyzed.Results Intraoperative hemorrhage and the use of electrocoagulation in the injection group were significantly less than those in the control group,there was significant difference between the two groups(x2=3.955,P<0.05).The incidence of recurrent vitreous hemorrhage and re-operation in the injection group was significantly lower than those in the control group,there was significant difference between the two groups(x2=4.084,P<0.05).The incidence of ocular hypertension in the injection group was significantly lower than that in the control group(x2=4.084,P<0.05).However,there was no significant difference in operative time between the two groups(t=0.248,P>0.05).What’s more,The use of intraocular implants in the injection group was less than that in the control group,but there was no significant difference in the number of eyes between the two groups(x2=0.013,P>0.05).The rate of vision improvement during the 6 months after the 23 G vitrectomy of the injection group was higher than that of the control group,but there was no significant difference between the two groups(P>0.05).Conclusion After the above treatment,intravitreal anti-VEGF drug injection before 23 G vitrectomy in PDR patients can reduce the occurrence of intraoperative bleeding,the use rate of intraoperative electrocoagulation,and the occurrence of postoperative complications,these include rebleeding,Retinal detachment,and elevated intraocular pressure,which in turn reduce the risk of reoperation.However,there was no significant difference between the two groups in the use of intraoperative Tamponade,the operation time and the improvement of postoperative visual acuity.
Keywords:Proliferative diabetic retinopathy  23G vitrectomy  Anti-vascular endothelial growth factor
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号